Spotlight BIOMATRIX™ COMFORTABLE AMI Data Published in JAMA
The first published study to demonstrate that a drug-eluting stent is superior to a bare-metal stent in the treatment of STEMI patients
Spotlight LEADERS LEADERS 5-Year Results presented at TCTFinal results from the groundbreaking LEADERS study were presented during TCT 2012. LEADERS was the first head-to-head randomized clinical study (RCT) between two limus-eluting stents, the first RCT between two stents to involve an "all-comers" patient population, and the first to be independently monitored and assessed by its investigators.
Axxess™ Axxess™ - Self-expanding bifurcation DES, is Biosensors’ dedicated bifurcation DES The device is the first BA9™-eluting dedicated bifurcation stent, complementing the existing BioMatrix family of product. It features our PLA/BA9™ technology, with an abluminal* biodegradable coating.
* The coating is applied primarily on the abluminal surface.
FY13 Results Webcast FY13 Fourth Quarter & Full Year Financial Results Briefing
Wednesday, 29 May 2013
7pm Singapore time
1pm CET
6am EST
7pm Singapore time
1pm CET
6am EST